多发性骨髓瘤预后因素的研究进展  

Research Progress on Prognostic Factors of Multiple Myeloma——Review

作　　者：马柯娃 孙超[1] 李建勇[2] 周新[1] MA Ke-Wa;SUN Chao;LI Jian-Yong;ZHOU Xin(Department of Hematology,Wuxi People’s Hospital Affiliated to Nanjing Medical University,Wuxi 214023,Jiangsu Province,China;Department of Hematology,The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,Jiangsu Province,China)

机构地区：[1]南京医科大学附属无锡市人民医院血液科,江苏无锡214023 [2]南京医科大学第一附属医院血液科,江苏南京210029

出　　处：《中国实验血液学杂志》2021年第4期1346-1350,共5页Journal of Experimental Hematology

摘　　要：目前,由于多发性骨髓瘤(MM)仍无法治愈,研究MM预后因素显得尤为重要。近年来,基于肿瘤或宿主特性,完整疾病分期系统如梅奥mSMART、虚弱性评分等进行了更新和改进,而其他独立预后因素如微小残留病灶、循环肿瘤DNA、红细胞分布宽度、淋巴细胞比值和胸苷激酶1等亦从不同角度显示了对MM预后评估的良好价值。对这些预后因素综合研究有助于区分出高风险MM患者以指导治疗,有望更好地改善MM患者生活质量。本文就近年影响MM预后因素的最新研究进展作一综述。At present, multiple myeloma(MM) still can not be cured, so it is particularly important to study the prognostic factors of MM. Recently, based on the characteristics of tumor or host, the complete disease staging systems,such as Mayor mSMART and frailty scoring system have been updated. Other independent prognostic factors, such as minimal residual disease, circulating tumor DNA, red blood cell distribution width, lymphocyte ratio and thymidine kinase 1 are of great value in evaluating the prognosis of MM from different perspectives. The comprehensive study about these prognostic factors is helpful to identify patients with high-risk MM to guide treatment and hopefully improves the quality of life of patients. In this review, the latest research progress of prognostic factors for MM is summarized briefly.

关 键 词：多发性骨髓瘤 预后 危险分层 

分 类 号：R733.3[医药卫生—肿瘤]